#TITLE_ALTERNATIVE#

• Main Author: NIM : 20714027, AZTRIANA
• Format: Theses
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/21368
• Institution: Institut Teknologi Bandung

Diabetes mellitus (DM) is a metabolic disorder disease with a long treatment time. The first choice drug for type 2 diabetes is metformin. In the treatment of DM, patients sometimes combine the drug with herbs. One known has been used for DM is mangosteen pericarp containing α-mangostin. This study was aimed to evaluate the pharmacokinetic and pharmacodynamic interactions of α-mangostin and metformin when used simultaneously in insulin resistant male rats. Tests were performed on five groups of insulin resistant male rats (n = 5 group metformin and n=6 group α-mangostin) in anesthesia by urethane anesthesia. Group I (MFN) was given a single dose of met(100 mg / Kg BW), Group II (AM) was given single-dose α-mangostin (37.2 mg / Kg BW), Group III (MFN + AM) was given single-dose metformin and α-mangostin, group IV (MFN 10 + AM) was given metformin for 10 days with single-dose α-mangostin, group V was control. Metformin and α-mangostin levels in plasma are determined by the HPLC method and plasma glucose levels were calculated by the GOD-PAP method. Pharmacokinetic profiles and parameters α-mangostin and metformin were calculated, percent decrease in blood glucose was calculated and dose-response curve of alpha mangostin and metformin was made. Pharmacokinetic profiles of metformin and alpha mangostin showed the two-compartment model, from either single or combination administration. The β of metformin showed a significan change (p>0,05) in group III (decreased 33,18 %) and group IV (decreased 46,05%) when compared to group I. And t½ biological parameters of metformin in group III (increased 31,25 %) and group IV (increased 47,90%) when compared to group I. This indicated that there was an interaction in the elimination phase. In contrast, pharmacokinetic parameters of α-mangostin did not change significantly. A study of pharmacodynamics based on AAC0-12 calculations showed no significant change in either metformin or α-mangostin in either single or repeated doses. However, combination administration showed an increase in the antihyperglycemic effect of metformin and α-mangostin. The combination of both produces a longer-lasting effect of blood glucose.